UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 495

Sortiert nach

Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial

Frontiers in immunology, 2023-04, Vol.14, p.1168879-1168879

2023

Volltextzugriff (PDF)

Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients

Thoracic cancer, 2020-06, Vol.11 (6), p.1621-1632

2020

Volltextzugriff (PDF)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis

Thoracic cancer, 2020-01, Vol.11 (1), p.191-197

2020

Volltextzugriff (PDF)

Penetration of the blood–brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation

Lung cancer (Amsterdam, Netherlands), 2018-08, Vol.122, p.1-6

2018

Volltextzugriff (PDF)

Assessment of CD27 expression on T-cells as a diagnostic and therapeutic tool for patients with smear-negative pulmonary tuberculosis

BMC immunology, 2021-06, Vol.22 (1), p.41-41, Article 41

2021

Volltextzugriff (PDF)

Pyrotinib‐associated acute kidney injury: A case report

Cancer innovation (Print), 2022-12, Vol.1 (4), p.344-347

2022

Volltextzugriff (PDF)

Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non‐small cell lung cancer patients

Thoracic cancer, 2020-06, Vol.11 (6), p.1647-1654

2020

Volltextzugriff (PDF)

Savolitinib versus crizotinib for treating MET positive non‐small cell lung cancer

Thoracic cancer, 2023-05, Vol.14 (13), p.1162-1170

2023

Volltextzugriff (PDF)

Prognostic biomarkers and immune cell infiltration characteristics in small cell lung cancer

Cancer pathogenesis and therapy, 2023-01, Vol.1 (1), p.18-24

2023

Volltextzugriff (PDF)

Opportunistic infections complicating immunotherapy for non‐small cell lung cancer

Thoracic cancer, 2020-06, Vol.11 (6), p.1689-1694

2020

Volltextzugriff (PDF)

Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor‐induced renal immune‐related adverse events

Thoracic cancer, 2020-06, Vol.11 (6), p.1746-1751

2020

Volltextzugriff (PDF)

Corrigendum: Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non- small cell lung cancer

Frontiers in immunology, 2022-12, Vol.13, p.1111230-1111230

2022

Volltextzugriff (PDF)

Multiple infections of zoonotic pathogens in wild Brandt's voles (Lasiopodomys brandtii)

Veterinary medicine and science, 2023-09, Vol.9 (5), p.2201-2211

2023

Volltextzugriff (PDF)

Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China

Frontiers in oncology, 2022-03, Vol.12, p.859938-859938

2022

Volltextzugriff (PDF)

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib

Thoracic cancer, 2020-03, Vol.11 (3), p.594-602

2020

Volltextzugriff (PDF)

The development of a tumor‐associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor‐based treatment in patients with advanced non‐small‐cell lung cancer

Thoracic cancer, 2023-02, Vol.14 (5), p.497-505

2023

Volltextzugriff (PDF)

Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303

Thoracic cancer, 2019-03, Vol.10 (3), p.551-556

2019

Volltextzugriff (PDF)

Histologic transformation of lung cancer during pembrolizumab therapy: A case report

Thoracic cancer, 2020-03, Vol.11 (3), p.793-796

2020

Volltextzugriff (PDF)

Clinical characteristics and prognostic model for extensive‐stage small cell lung cancer: A retrospective study over an 8‐year period

Thoracic cancer, 2022-02, Vol.13 (4), p.539-548

2022

Volltextzugriff (PDF)

Management of immune checkpoint inhibitor‐related dermatologic adverse events

Thoracic cancer, 2020-02, Vol.11 (2), p.488-492

2020

Volltextzugriff (PDF)

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events

Thoracic cancer, 2020-03, Vol.11 (3), p.799-804

2020

Volltextzugriff (PDF)

A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer

Therapeutic advances in medical oncology, 2020, Vol.12, p.1758835920965849-1758835920965849

2020

Volltextzugriff (PDF)

Genomic characteristics of driver genes in Chinese patients with non‐small cell lung cancer

Thoracic cancer, 2021-02, Vol.12 (3), p.357-363

2021

Volltextzugriff (PDF)

Pulmonary and Skeletal Infection of Mycobacterium kansasii

American journal of respiratory and critical care medicine, 2020-10, Vol.202 (8), p.1169-1170

2020

Volltextzugriff (PDF)

Single‐center study to determine the safety and efficacy of CT‐707 in Chinese patients with advanced anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer

Thoracic cancer, 2020-05, Vol.11 (5), p.1216-1223

2020

Volltextzugriff (PDF)

1 – 25 von 495

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(447)
Mit Volltextzugriff
(473)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(354)
Life Sciences & Biomedicine
(239)
Humans
(129)
Technology
(85)
Physical Sciences
(78)
Oncology
(72)
Animals
(60)
Chemistry
(55)
Materials Science
(49)
Male
(47)
Female
(42)
Patients
(40)
Engineering
(39)
Materials Science, Multidisciplinary
(39)
Respiratory System
(39)
Lung Cancer
(38)
Immunotherapy
(32)
Apoptosis
(30)
Mice
(28)
Adult
(27)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial

Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis

Penetration of the blood–brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation

Assessment of CD27 expression on T-cells as a diagnostic and therapeutic tool for patients with smear-negative pulmonary tuberculosis

Pyrotinib‐associated acute kidney injury: A case report

Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non‐small cell lung cancer patients

Savolitinib versus crizotinib for treating MET positive non‐small cell lung cancer

Prognostic biomarkers and immune cell infiltration characteristics in small cell lung cancer

Opportunistic infections complicating immunotherapy for non‐small cell lung cancer

Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor‐induced renal immune‐related adverse events

Corrigendum: Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non- small cell lung cancer

Multiple infections of zoonotic pathogens in wild Brandt's voles (Lasiopodomys brandtii)

Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib

The development of a tumor‐associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor‐based treatment in patients with advanced non‐small‐cell lung cancer

Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303

Histologic transformation of lung cancer during pembrolizumab therapy: A case report

Clinical characteristics and prognostic model for extensive‐stage small cell lung cancer: A retrospective study over an 8‐year period

Management of immune checkpoint inhibitor‐related dermatologic adverse events

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events

A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer

Genomic characteristics of driver genes in Chinese patients with non‐small cell lung cancer

Pulmonary and Skeletal Infection of Mycobacterium kansasii

Single‐center study to determine the safety and efficacy of CT‐707 in Chinese patients with advanced anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer

Suchergebnisse filtern